Your browser doesn't support javascript.
Associations between resources and practices of ILD centers and outcomes in patients with idiopathic pulmonary fibrosis: data from the IPF-PRO Registry.
de Andrade, Joao A; Kulkarni, Tejaswini; Neely, Megan L; Hellkamp, Anne S; Case, Amy Hajari; Culver, Daniel A; Guntupalli, Kalpalatha; Bender, Shaun; Conoscenti, Craig S; Snyder, Laurie D.
  • de Andrade JA; Vanderbilt University School of Medicine, Nashville, TN, USA. joao.de.andrade@vumc.org.
  • Kulkarni T; University of Alabama at Birmingham, Birmingham, AL, USA.
  • Neely ML; Duke Clinical Research Institute, Durham, NC, USA.
  • Hellkamp AS; Duke University Medical Center, Durham, NC, USA.
  • Case AH; Duke Clinical Research Institute, Durham, NC, USA.
  • Culver DA; Duke University Medical Center, Durham, NC, USA.
  • Guntupalli K; Piedmont Healthcare, Atlanta, GA, USA.
  • Bender S; Cleveland Clinic, Cleveland, OH, USA.
  • Conoscenti CS; Baylor College of Medicine, Houston, TX, USA.
  • Snyder LD; Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA.
Respir Res ; 23(1): 3, 2022 Jan 07.
Article in English | MEDLINE | ID: covidwho-1631557
ABSTRACT

BACKGROUND:

Performance benchmarks for the management of idiopathic pulmonary fibrosis (IPF) have not been established. We used data from the IPF-PRO Registry, an observational registry of patients with IPF managed at sites across the US, to examine associations between the characteristics of the enrolling sites and patient outcomes.

METHODS:

An online survey was used to collect information on the resources, operations, and self-assessment practices of IPF-PRO Registry sites that enrolled ≥ 10 patients. Site variability in 1-year event rates of clinically relevant outcomes, including death, death or lung transplant, and hospitalization, was assessed. Models were adjusted for differences in patient case mix by adjusting for known predictors of each outcome. We assessed whether site-level heterogeneity existed for each patient-level outcome, and if so, we investigated potential drivers of the heterogeneity.

RESULTS:

All 27 sites that enrolled ≥ 10 patients returned the questionnaire. Most sites were actively following > 100 patients with IPF (70.4%), had a lung transplant program (66.7%), and had a dedicated ILD nurse leader (77.8%). Substantial heterogeneity was observed in the event rates of clinically relevant outcomes across the sites. After controlling for patient case mix, there were no outcomes for which the site variance component was significantly different from 0, but the p-value for hospitalization was 0.052. Starting/completing an ILD-related quality improvement project in the previous 2 years was associated with a lower risk of hospitalization (HR 0.60 [95% CI 0.44, 0.82]; p = 0.001).

CONCLUSIONS:

Analyses of data from patients with IPF managed at sites across the US found no site-specific characteristics or practices that were significantly associated with clinically relevant outcomes after adjusting for patient case mix. Trial registration ClinicalTrials.gov, NCT01915511. Registered 5 August 2013, https//clinicaltrials.gov/ct2/show/NCT01915511.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Registries / Lung Transplantation / Idiopathic Pulmonary Fibrosis / Hospitalization Type of study: Cohort study / Observational study / Prognostic study / Randomized controlled trials Limits: Aged / Female / Humans / Male / Middle aged Language: English Journal: Respir Res Year: 2022 Document Type: Article Affiliation country: S12931-021-01921-7

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Registries / Lung Transplantation / Idiopathic Pulmonary Fibrosis / Hospitalization Type of study: Cohort study / Observational study / Prognostic study / Randomized controlled trials Limits: Aged / Female / Humans / Male / Middle aged Language: English Journal: Respir Res Year: 2022 Document Type: Article Affiliation country: S12931-021-01921-7